| Tuesday, March 10th 2020

Interview of Herantis Pharma CEO on Q4 2019 by Direkt Studios

| Friday, February 28th 2020

CDNF phase I-II clinical study webinar: Topline data of the 6-month treatment period

| Wednesday, February 26th 2020

Renishaw announces completion of the main part of a multi-centre clinical trial

| Tuesday, February 25th 2020

Herantis Pharma Plc announces topline results of Phase 1-2 CDNF trial

| Saturday, January 4th 2020

Patient Treatment Completed in Phase 1/2 Trial Testing Therapy Candidate CDNF in Parkinson’s Disease

Parkinson's News Today
| Tuesday, May 7th 2019

Novel drug delivered direct 2 brain may halt Parkinson’s

| Thursday, March 28th 2019

Henri Huttunen, CSO of Herantis Pharma introducing results of first-in-human CDNF phase I-II clinical trial in AD/PD 2019

| Friday, July 6th 2018

Herantis initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki